Mark Talamonti to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Mark Talamonti has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.579
-
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020 06; 20(6):665-672.
Score: 0.491
-
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019 05; 32(3):e12899.
Score: 0.465
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
Score: 0.118
-
Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2016 Dec; 12(12):1255-1271.
Score: 0.098
-
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug; 169(2):458-63.
Score: 0.078
-
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol. 2012; 2012:823854.
Score: 0.072
-
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
Score: 0.067
-
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology. 2011; 222(3):250-5.
Score: 0.067
-
The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010 Oct 01; 102(5):539-42.
Score: 0.064
-
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):958-964.
Score: 0.033
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.014
-
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol. 2007 Apr; 156 Suppl 2:17-23.
Score: 0.013